Global Anti-Obesity Prescription market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. Get Access Now!

Global Anti-Obesity Prescription Market Size and Outlook 2025-31

The global Anti-Obesity Prescription market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report. Obesity is a public health problem. Obesity is a genetic and chronic metabolic disease involving accumulation of excessive or abnormal fat in the body. It contributes to risk of chronic conditions such as cancer, hypertension, cardiovascular diseases, diabetics, obstructive sleep apnea, ventilatory failure, renal failure and asthma. According to a World Health Organization (WHO) report published in 2014, around 3.4 million adults in the world die each year due to obesity related issues. Increasing prevalence of obesity among children and adults is posing a threat and developing nations. Effective intervention strategies such as increased physical activity, behavioral and dietary changes are commonly used to control and prevent obesity. Obesity has a major impact on population longevity and health related expense. According to our Wellness & Health Research Center, the global wellness & health economy was valued at US dollars 4.8 trillion. Asia Pacific was the region with the highest spending on big health in 2022, with a total spending of $1.68 trillion, followed by North America ($1.42 trillion) and Europe ($1.0 trillion). According to the health industry accounting analysis data disclosed by the Health Development Research Center of the National Health Commission, from 2019 to 2021, the market size of the health service industry grew by an average of 7.0% per year, and the specific data increased from 7.7 trillion yuan to 8.8 trillion yuan. Chinas health industry revenue reached 8.0 trillion yuan in 2021, with an increase of 8.1%. According to public information, in 2022, there were about 1.2 billion obesity cases worldwide, among them, the number of obesity cases in China reached 230 million. Wellness & Health Research Center, the global sports economy was valued at 750 billion in 2022, 92% of global spending on physical activity occurs in Asia Pacific, North America and Europe. And China and the United States accounted for 44% of total sports spending. Infinity Market Research newest research report, the Anti-Obesity Prescription Industry Forecast looks at past sales and reviews total world Anti-Obesity Prescription sales in 2024, providing a comprehensive analysis by region and market sector of projected Anti-Obesity Prescription sales for 2025 through 2031. With Anti-Obesity Prescription sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-Obesity Prescription industry. This Insight Report provides a comprehensive analysis of the global Anti-Obesity Prescription landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-Obesity Prescription portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Anti-Obesity Prescription market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-Obesity Prescription and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-Obesity Prescription. This report presents a comprehensive overview, market shares, and growth opportunities of Anti-Obesity Prescription market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Bupropion and Naltrexone &nbsp;&nbsp;&nbsp; Orlistat &nbsp;&nbsp;&nbsp; Lorcaserin &nbsp;&nbsp;&nbsp; Phentermine and Topiramate &nbsp;&nbsp;&nbsp; Liraglutide Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospital Pharmacies &nbsp;&nbsp;&nbsp; Retail Pharmacies &nbsp;&nbsp;&nbsp; E-Commerce This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Zydus Cadila &nbsp;&nbsp;&nbsp; Akrimax Pharmaceuticals &nbsp;&nbsp;&nbsp; Zealand Pharma &nbsp;&nbsp;&nbsp; Arrowhead Research &nbsp;&nbsp;&nbsp; Arena Pharmaceuticals &nbsp;&nbsp;&nbsp; Compellis Pharmaceuticals &nbsp;&nbsp;&nbsp; Yungjin Pharm &nbsp;&nbsp;&nbsp; Alpex Pharma &nbsp;&nbsp;&nbsp; Bridge BioResearch Key Questions Addressed in this Report What is the 10-year outlook for the global Anti-Obesity Prescription market? What factors are driving Anti-Obesity Prescription market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Anti-Obesity Prescription market opportunities vary by end market size? How does Anti-Obesity Prescription break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Anti-Obesity Prescription Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Anti-Obesity Prescription by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Anti-Obesity Prescription by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Anti-Obesity Prescription Segment by Type &nbsp;2.2.1 Bupropion and Naltrexone &nbsp;2.2.2 Orlistat &nbsp;2.2.3 Lorcaserin &nbsp;2.2.4 Phentermine and Topiramate &nbsp;2.2.5 Liraglutide &nbsp;2.3 Anti-Obesity Prescription Sales by Type &nbsp;2.3.1 Global Anti-Obesity Prescription Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Anti-Obesity Prescription Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Anti-Obesity Prescription Sale Price by Type (2020-2025) &nbsp;2.4 Anti-Obesity Prescription Segment by Application &nbsp;2.4.1 Hospital Pharmacies &nbsp;2.4.2 Retail Pharmacies &nbsp;2.4.3 E-Commerce &nbsp;2.5 Anti-Obesity Prescription Sales by Application &nbsp;2.5.1 Global Anti-Obesity Prescription Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Anti-Obesity Prescription Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Anti-Obesity Prescription Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Anti-Obesity Prescription Breakdown Data by Company &nbsp;3.1.1 Global Anti-Obesity Prescription Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Anti-Obesity Prescription Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Anti-Obesity Prescription Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Anti-Obesity Prescription Revenue by Company (2020-2025) &nbsp;3.2.2 Global Anti-Obesity Prescription Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Anti-Obesity Prescription Sale Price by Company &nbsp;3.4 Key Manufacturers Anti-Obesity Prescription Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Anti-Obesity Prescription Product Location Distribution &nbsp;3.4.2 Players Anti-Obesity Prescription Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Anti-Obesity Prescription by Geographic Region &nbsp;4.1 World Historic Anti-Obesity Prescription Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Anti-Obesity Prescription Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Anti-Obesity Prescription Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Anti-Obesity Prescription Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Anti-Obesity Prescription Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Anti-Obesity Prescription Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Anti-Obesity Prescription Sales Growth &nbsp;4.4 APAC Anti-Obesity Prescription Sales Growth &nbsp;4.5 Europe Anti-Obesity Prescription Sales Growth &nbsp;4.6 Middle East & Africa Anti-Obesity Prescription Sales Growth 5 Americas &nbsp;5.1 Americas Anti-Obesity Prescription Sales by Country &nbsp;5.1.1 Americas Anti-Obesity Prescription Sales by Country (2020-2025) &nbsp;5.1.2 Americas Anti-Obesity Prescription Revenue by Country (2020-2025) &nbsp;5.2 Americas Anti-Obesity Prescription Sales by Type (2020-2025) &nbsp;5.3 Americas Anti-Obesity Prescription Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Anti-Obesity Prescription Sales by Region &nbsp;6.1.1 APAC Anti-Obesity Prescription Sales by Region (2020-2025) &nbsp;6.1.2 APAC Anti-Obesity Prescription Revenue by Region (2020-2025) &nbsp;6.2 APAC Anti-Obesity Prescription Sales by Type (2020-2025) &nbsp;6.3 APAC Anti-Obesity Prescription Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Anti-Obesity Prescription by Country &nbsp;7.1.1 Europe Anti-Obesity Prescription Sales by Country (2020-2025) &nbsp;7.1.2 Europe Anti-Obesity Prescription Revenue by Country (2020-2025) &nbsp;7.2 Europe Anti-Obesity Prescription Sales by Type (2020-2025) &nbsp;7.3 Europe Anti-Obesity Prescription Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Anti-Obesity Prescription by Country &nbsp;8.1.1 Middle East & Africa Anti-Obesity Prescription Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Anti-Obesity Prescription Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Anti-Obesity Prescription Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Anti-Obesity Prescription Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Anti-Obesity Prescription &nbsp;10.3 Manufacturing Process Analysis of Anti-Obesity Prescription &nbsp;10.4 Industry Chain Structure of Anti-Obesity Prescription 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Anti-Obesity Prescription Distributors &nbsp;11.3 Anti-Obesity Prescription Customer 12 World Forecast Review for Anti-Obesity Prescription by Geographic Region &nbsp;12.1 Global Anti-Obesity Prescription Market Size Forecast by Region &nbsp;12.1.1 Global Anti-Obesity Prescription Forecast by Region (2026-2031) &nbsp;12.1.2 Global Anti-Obesity Prescription Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Anti-Obesity Prescription Forecast by Type (2026-2031) &nbsp;12.7 Global Anti-Obesity Prescription Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Zydus Cadila &nbsp;13.1.1 Zydus Cadila Company Information &nbsp;13.1.2 Zydus Cadila Anti-Obesity Prescription Product Portfolios and Specifications &nbsp;13.1.3 Zydus Cadila Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Zydus Cadila Main Business Overview &nbsp;13.1.5 Zydus Cadila Latest Developments &nbsp;13.2 Akrimax Pharmaceuticals &nbsp;13.2.1 Akrimax Pharmaceuticals Company Information &nbsp;13.2.2 Akrimax Pharmaceuticals Anti-Obesity Prescription Product Portfolios and Specifications &nbsp;13.2.3 Akrimax Pharmaceuticals Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Akrimax Pharmaceuticals Main Business Overview &nbsp;13.2.5 Akrimax Pharmaceuticals Latest Developments &nbsp;13.3 Zealand Pharma &nbsp;13.3.1 Zealand Pharma Company Information &nbsp;13.3.2 Zealand Pharma Anti-Obesity Prescription Product Portfolios and Specifications &nbsp;13.3.3 Zealand Pharma Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Zealand Pharma Main Business Overview &nbsp;13.3.5 Zealand Pharma Latest Developments &nbsp;13.4 Arrowhead Research &nbsp;13.4.1 Arrowhead Research Company Information &nbsp;13.4.2 Arrowhead Research Anti-Obesity Prescription Product Portfolios and Specifications &nbsp;13.4.3 Arrowhead Research Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Arrowhead Research Main Business Overview &nbsp;13.4.5 Arrowhead Research Latest Developments &nbsp;13.5 Arena Pharmaceuticals &nbsp;13.5.1 Arena Pharmaceuticals Company Information &nbsp;13.5.2 Arena Pharmaceuticals Anti-Obesity Prescription Product Portfolios and Specifications &nbsp;13.5.3 Arena Pharmaceuticals Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Arena Pharmaceuticals Main Business Overview &nbsp;13.5.5 Arena Pharmaceuticals Latest Developments &nbsp;13.6 Compellis Pharmaceuticals &nbsp;13.6.1 Compellis Pharmaceuticals Company Information &nbsp;13.6.2 Compellis Pharmaceuticals Anti-Obesity Prescription Product Portfolios and Specifications &nbsp;13.6.3 Compellis Pharmaceuticals Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Compellis Pharmaceuticals Main Business Overview &nbsp;13.6.5 Compellis Pharmaceuticals Latest Developments &nbsp;13.7 Yungjin Pharm &nbsp;13.7.1 Yungjin Pharm Company Information &nbsp;13.7.2 Yungjin Pharm Anti-Obesity Prescription Product Portfolios and Specifications &nbsp;13.7.3 Yungjin Pharm Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Yungjin Pharm Main Business Overview &nbsp;13.7.5 Yungjin Pharm Latest Developments &nbsp;13.8 Alpex Pharma &nbsp;13.8.1 Alpex Pharma Company Information &nbsp;13.8.2 Alpex Pharma Anti-Obesity Prescription Product Portfolios and Specifications &nbsp;13.8.3 Alpex Pharma Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 Alpex Pharma Main Business Overview &nbsp;13.8.5 Alpex Pharma Latest Developments &nbsp;13.9 Bridge BioResearch &nbsp;13.9.1 Bridge BioResearch Company Information &nbsp;13.9.2 Bridge BioResearch Anti-Obesity Prescription Product Portfolios and Specifications &nbsp;13.9.3 Bridge BioResearch Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Bridge BioResearch Main Business Overview &nbsp;13.9.5 Bridge BioResearch Latest Developments 14 Research Findings and Conclusion

Report	Global Anti-Obesity Prescription Market Growth 2025-2031
Selected License	Multi ID: LPI24014

Buyer Information

Order Summary